FABP1 and IgA glomerulonephritis: Urinary L-FABP has been identified in preclinical and clinical models and has been found to be a potential biomarker in a number of pathologic conditions, including CKD, diabetic nephropathy, IgA nephropathy, and contrast nephropathy.